

Important product update from Boehringer Ingelheim Animal Health UK Limited



Disruption to Pexion® supply

Due to the impact of the Covid-19 pandemic at one of our manufacturing sites, we are facing a period of temporary supply disruption with Pexion®, our product for canine idiopathic epilepsy and noise phobia. The manufacturing site that produces Pexion® for the UK, Ireland and the rest of Europe is located in a region which is badly impacted by the Covid-19 pandemic. Please be reassured that we are doing all we can to minimise this impact.

We understand how critical Pexion® is to your patients, and we have taken immediate steps to help protect supply for those patients most in need. With immediate effect, Pexion® 100 mg and 400 mg tablets will be allocated by our Technical Services Team on a case-by-case basis according to clinical need until we can re-establish supply. During the call we may ask you to transition suitable cases from Pexion® 400 mg tablets to 100 mg tablets to protect supply for larger dogs and those on significant doses. Veterinary practices can access email templates, which may be helpful to ask clients to place repeat prescription requests for Pexion® early, via this link: bit.ly/BIAHSupport

To ensure product availability for critical patients, we would kindly request that you:

**Please avoid starting any new patients on Pexion®
until the supply situation is resolved**

We understand the challenges your practice has faced during the Covid-19 pandemic and the pressure it has put on you and your team. We are sorry to cause any further disruption during these difficult times. Thank you for your continued support and understanding.

If you have a specific case for which you require Pexion® 100 mg or 400 mg tablets, please contact our **Technical Services Team on 01344 746957**.